发明名称 ARYLOXY-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES
摘要 <p>A glucokinase activator is provided; and a treatment and/or a preventive for diabetes, or a treatment and/or a preventive for diabetes such as retinopathy, nephropathy, neurosis, ischemic cardiopathy, arteriosclerosis, and further a treatment and/or a preventive for obesity are provided. The invention relates to a compound of a formula (I): [wherein R 1 and R 2 represent a hydrogen, etc.; R 3 represents a hydrogen atom, a halogen atom, etc.; R 4 each independently represents a hydrogen atom, a lower alkyl group, etc.; Q represents a carbon atom, a nitrogen atom or a sulfur atom (the sulfur atom may be mono- or di-substituted with an oxo group); R 5 and R6 each represent a hydrogen atom, a lower alkyl group, etc.; X 1 , X 2 , X 3 and X 4 each independently represent a carbon atom or a nitrogen atom; Z represents an oxygen atom, a sulfur atom or a nitrogen atom; Ar represents an aryl or heteroaryl group optionally mono to tri-substituted with a group selected from the substituent group ²; ring A represents a 5- or 6-membered nitrogen-containing heteroaromatic group; m indicates an integer of from 1 to 6; n indicates an integer of from 0 to 3; p indicates an integer of from 0 to 2 (provided that at least two of X 1 to X 4 are carbon atoms); q indicates 0 or 1] or its pharmaceutically-acceptable salt, which has an effect of glucokinase activation and is useful as a treatment for diabetes.</p>
申请公布号 EP1810969(A1) 申请公布日期 2007.07.25
申请号 EP20050803447 申请日期 2005.11.01
申请人 BANYU PHARMACEUTICAL CO., LTD. 发明人 HASHIMOTO, N.;TAKAHASHI, K.;NAKAMA, C.;OGINO, Y.;SAKAI, F.;NISHIMURA, T.;EIKI, J.
分类号 C07D401/04;A61K31/155;A61K31/4439;A61K31/444;A61K31/4545;A61K31/497;A61K31/506;A61K38/22;A61K38/26;A61K45/00;A61P3/04;C07D401/14;C07D413/06;C07D413/14 主分类号 C07D401/04
代理机构 代理人
主权项
地址